Tyrosine Kinase Inhibitors [MoA] class drugs

7 results
  • alunbrig - brigatinib tablet, film coated

    (Brigatinib)
    Takeda Pharmaceuticals America, Inc.
    Alunbrig treats adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
  • ayvakit - avapritinib tablet, film coated

    (Avapritinib)
    Blueprint Medicines Corporation
    Ayvakit treats adults with unresectable or metastatic GIST harboring PDGFRA exon 18 mutations (including D842V), advanced systemic mastocytosis (ASM, SM-AHN, mast cell leukemia), and indolent systemic mastocytosis. Not recommended when platelet counts are below 50 × 10⁹/L.
  • calquence - acalabrutinib tablet, film coated

    (Acalabrutinib)
    Astrazeneca Pharmaceuticals Lp
    CALQUENCE treats adults with mantle cell lymphoma (MCL) — either previously untreated (with bendamustine and rituximab, when ineligible for stem cell transplant) or after prior therapy — and adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • tukysa - tucatinib tablet

    (Tucatinib)
    Seagen Inc.
    Tukysa is used with trastuzumab and capecitabine for HER2-positive metastatic breast cancer (including brain metastases) in adults after prior anti-HER2 therapy. Also used with trastuzumab for RAS wild-type, HER2-positive metastatic colorectal cancer after prior chemotherapy.
  • vonjo - pacritinib capsule

    (Pacritinib)
    Sobi, Inc.
    Vonjo treats adults with intermediate or high-risk primary or secondary myelofibrosis (post-polycythemia vera or post-essential thrombocythemia) with a platelet count below 50 × 10⁹/L. Approved under accelerated approval based on spleen volume reduction.